Safer Warfarin Treatment (CYKOWAR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01042067|
Recruitment Status : Suspended (Enrolling participants has halted due to lack of investigator.)
First Posted : January 5, 2010
Last Update Posted : April 27, 2011
|Condition or disease||Intervention/treatment|
|Atrial Fibrillation Venous Thrombosis Pulmonary Embolism Heart Valve Prosthesis||Other: Blood specimens (whole blood, serum, plasma)|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Safer Warfarin Treatment - the Influence of CYP2C9 Genotyping, Genotyping of Vitamine K Dependent Proteins and Dietary Vitamine K Status on Dosing, Clinical Effect and Adverse Events With Emphasis on the Initial Phase of Treatment|
|Study Start Date :||January 2010|
Warfarin treatment group
Open label study. Patients in need of warfarin treatment (standard indications) are included in the study at the onset of warfarin treatment.
Other: Blood specimens (whole blood, serum, plasma)
The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01042067
|Oslo University Hospital|
|Oslo, Norway, N-0407|